What is Leerink Partnrs’ Forecast for MNMD Q1 Earnings?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Mind Medicine (MindMed) in a research note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman forecasts that the company will earn ($0.35) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share.

Several other analysts have also issued reports on MNMD. Evercore ISI initiated coverage on Mind Medicine (MindMed) in a report on Tuesday. They set an “outperform” rating and a $23.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $55.00 price objective on shares of Mind Medicine (MindMed) in a research note on Monday, November 11th. Oppenheimer reissued an “outperform” rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a report on Tuesday, December 17th. Leerink Partners started coverage on shares of Mind Medicine (MindMed) in a report on Monday, October 14th. They set an “outperform” rating and a $20.00 price target on the stock. Finally, Chardan Capital began coverage on shares of Mind Medicine (MindMed) in a research report on Friday, December 20th. They issued a “buy” rating and a $20.00 price target for the company. Ten analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $26.33.

Mind Medicine (MindMed) Stock Performance

Shares of MNMD stock opened at $7.32 on Thursday. Mind Medicine has a 1 year low of $3.80 and a 1 year high of $12.22. The firm has a fifty day moving average price of $7.27 and a 200-day moving average price of $6.94. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its earnings results on Thursday, November 7th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. During the same quarter in the previous year, the firm earned ($0.53) EPS.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC bought a new position in Mind Medicine (MindMed) during the third quarter valued at $58,000. Sanctuary Advisors LLC bought a new position in shares of Mind Medicine (MindMed) in the 3rd quarter valued at about $91,000. Foundations Investment Advisors LLC bought a new position in shares of Mind Medicine (MindMed) in the 4th quarter valued at about $91,000. Stoneridge Investment Partners LLC purchased a new position in Mind Medicine (MindMed) in the third quarter worth about $93,000. Finally, SG Americas Securities LLC bought a new stake in Mind Medicine (MindMed) during the third quarter worth approximately $93,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Mind Medicine (MindMed)

In other Mind Medicine (MindMed) news, CEO Robert Barrow sold 19,106 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $7.43, for a total transaction of $141,957.58. Following the completion of the transaction, the chief executive officer now owns 526,666 shares in the company, valued at $3,913,128.38. This trade represents a 3.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Dan Karlin sold 6,643 shares of the company’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $7.43, for a total value of $49,357.49. Following the sale, the insider now directly owns 338,013 shares in the company, valued at $2,511,436.59. This trade represents a 1.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,022 shares of company stock valued at $208,203. 2.26% of the stock is currently owned by corporate insiders.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.